Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: National Institute of Standards and Technology ATP Program

This article was originally published in The Gray Sheet

Executive Summary

National Institute of Standards and Technology ATP Program: NIST launches $10-15 mil. research and development competition in "Information Infrastructure for Healthcare." The Advanced Technology Program competition, which is aimed at enabling "more efficient information systems tailored to the special needs of the nation's healthcare industry," includes fields such as business process modeling, verification and validation, information access, transmission, storage, security and mobile computing. Deadline for submission is 3 p.m. EST, April 30; a public meeting will be held Feb. 13 at the Gaithersburg, Maryland Hilton to discuss the ATP program and selection criteria. More information can be found at NIST's web site (http://www.atp.nist.gov)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT007347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel